Investigation of Three Biomarkers for the Detection of Prostate Cancer
NCT ID: NCT06554587
Last Updated: 2025-01-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
137 participants
OBSERVATIONAL
2025-01-07
2026-03-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a prospective, non-interventional study using venous blood samples taken from patients with suspected prostate cancer or on active surveillance, attending the hospital Urology department for a transperineal biopsy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Precision Medicine in the Prostate Cancer Care Pathway
NCT04763317
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
NCT03256630
Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence
NCT02070575
Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
NCT02705846
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The initial diagnosis of prostate cancer relies on the detection of PSA (prostate specific antigen) in patient blood. While PSA is relatively good at identifying prostate cancer, PSA levels can be elevated for reasons other than cancer (giving a false positive result). Two thirds of men with a raised PSA level don't have prostate cancer meaning that many men undergo unnecessary \& invasive follow up procedures, such as tissue biopsy. Prostate biopsies place a huge burden on both healthcare systems, and individuals with suspected prostate cancer. They are painful, can lead to complications, infections and in extreme circumstances, death.
Therefore, the poor specificity of the PSA test, combined with the disparate natural histories of many prostate cancers has limited its utility as a screening tool.
A combination of clinical and pathological features, such as the tumour grade (Gleason score or Gleason Grade Group), combined with clinical examination (digital rectal examination), MRI (magnetic resonance imaging) and isotope bone scan are commonly used to determine the aggressiveness and curability of tumours with radical treatment. PSA measurement is used as part of this assessment but, as other factors can influence PSA levels, it cannot be used to assess risk or guide treatment in isolation.
There remains an unmet clinical need for a better screening and diagnostic test for prostate cancer. Such a test must also be able to differentiate between early, low-risk cancers that do not require radical treatment and more aggressive tumours where radical treatment is preferable. By identifying which patients have a clinically significant risk of prostate cancer we believe our test could provide a solution to both.
The GlycoScore immunoassays detect the three biomarkers - 'glycosyltransferase enzymes' in patient blood (GALNT7, ST6GAL1 and GCNT1) which are linked to key tumour-associated glycans (types of sugars on cell walls) using an ELISA (enzyme-linked immunosorbent assay-based platform).
Initial studies conducted by Newcastle University using RUO (research use only) ELISA kits showed a significant correlation between prostate cancer and the three biomarkers ST6GAL1, GCNT1 and GALNT7. Extensive research and development work has been carried out developing custom antibody pairs and antigens for inclusion in our ELISA kit, as well as to optimize buffers and other components.
The purpose of this study is to obtain fresh patient blood samples to further evaluate the three biomarkers ST6GAL1, GCNT1 and GALNT7 for their ability to identify clinically significant prostate cancer, either alone, as a combination of the biomarkers or in combination with the PSA (measurement obtained at Medtechtomarket) using our in-house developed ELISA assays and a CE-marked PSA ELISA test kit.
Diagnostic accuracy for participants with prostate cancer will be determined by comparison with biopsy results, and for participants without prostate cancer, comparison with mpMRI (multi-parametric magnetic resonance imaging) and biopsy results.
Assessment of the correlation between the GlycoScore biomarker results with the full range of biopsy Gleason scores/Gleason Grade group/CPG grade (Cambridge Prognostic Group) will allow an assessment of the prognostic value of the GlycoScore test and its potential use in the clinical management of prostate cancer.
Patients attending the hospital for a transperineal prostate biopsy who are either being investigated for suspected prostate cancer or are undergoing active surveillance for previously diagnosed prostate cancer will be asked to consent to take part in the study. Patients will be asked to consent to have a small sample of blood taken before the biopsy and for study investigators to have access to their final diagnosis. The blood sample will be sent to Medtechtomarket Laboratories for measurement of the biomarkers and PSA. Patients will also be asked to consent to an additional tube of blood to be taken (from the same blood draw) and the urine sample, which is routinely taken before the biopsy to be sent to the Liverpool University Biobank for future use in research studies.
137 male patients aged 18 years and above will be recruited for the study which is expected to take 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with suspected prostate cancer or on active surveillance
Diagnostic tests to measure three separate biomarkers in blood taken from patients pre-biopsy to assess the diagnostic performance of the biomarkers in detecting clinically significant prostate cancer (Gleason score ≥7)
Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient is being investigated for suspected prostate cancer or is on active surveillance
* The patient is able to give consent to take part in the study
Exclusion Criteria
* A patient with an active urinary tract infection
* The patient has a prior diagnosis of any other cancer or is receiving any cancer treatment (including ADT)
* The patient is currently or within the last 4 months enrolled on another study involving an investigational medicinal product
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlycoscoreDx Ltd
UNKNOWN
Medtechtomarket Consulting Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Henry P Lazarowicz, FRCS(Urol)
Role: PRINCIPAL_INVESTIGATOR
Liverpool University Hospitals NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Liverpool University Hospital
Liverpool, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE; NHS Prostate Cancer Risk Management Programme. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005 Sep;48(3):386-99; discussion 398-9. doi: 10.1016/j.eururo.2005.04.015.
Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994 Dec;152(6 Pt 1):2037-42. doi: 10.1016/s0022-5347(17)32300-5.
Johnston E, Pye H, Bonet-Carne E, Panagiotaki E, Patel D, Galazi M, Heavey S, Carmona L, Freeman A, Trevisan G, Allen C, Kirkham A, Burling K, Stevens N, Hawkes D, Emberton M, Moore C, Ahmed HU, Atkinson D, Rodriguez-Justo M, Ng T, Alexander D, Whitaker H, Punwani S. INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer. BMC Cancer. 2016 Oct 21;16(1):816. doi: 10.1186/s12885-016-2856-2.
Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009 Jan;8(1):113-7. doi: 10.1021/pr800545q.
Flahault A, Cadilhac M, Thomas G. Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol. 2005 Aug;58(8):859-62. doi: 10.1016/j.jclinepi.2004.12.009.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Prostate cancer: diagnosis and management - current UK NICE guidelines
Current NICE guidelines - Evidence review covering the definition of clinically significant prostate cancer, page 17
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M2M-GLYCOSCORE-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.